Edgewise Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:EWTX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 454.39 M613.33 M583.47 M552.6 M518.52 M479.69 M Total liabilities 24.67 M24.26 M24.82 M30.35 M25.32 M31.61 M Total equity 429.72 M589.07 M558.65 M522.26 M493.2 M448.08 M Total liabilities & shareholders' equities 454.39 M613.33 M583.47 M552.6 M518.52 M479.69 M Total debt —————— Net debt ——————

News

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

Tracking Baker Brothers Portfolio: Q1 2026 Update

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17

Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Edgewise Therapeutics (NASDAQ:EWTX)

Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?

Edgewise Stock: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement (EWTX)

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal